<div id="readability-page-1"><p>Neuberger Berman Group LLC lessened its stake in  AbbVie Inc. (NYSE:ABBV - Free Report) by 9.7% in the second quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 1,240,254 shares of the company's stock after selling 132,804 shares during the period. Neuberger Berman Group LLC owned 0.07% of AbbVie worth $230,216,000 at the end of the most recent quarter.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Other large investors have also recently bought and sold shares of the company. Conning Inc. increased its holdings in shares of  AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company's stock valued at $35,458,000 after buying an additional 12,690 shares in the last quarter.  Dohj LLC raised its position in shares of  AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company's stock worth $802,000 after purchasing an additional 1,335 shares during the period.  First Hawaiian Bank lifted its holdings in shares of  AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock valued at $1,403,000 after purchasing an additional 60 shares during the last quarter.  BankPlus Trust Department boosted its position in shares of  AbbVie by 3.3% in the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock valued at $5,033,000 after purchasing an additional 855 shares during the period.  Finally, Whittier Trust Co. increased its stake in  AbbVie by 4.0% in the 2nd quarter. Whittier Trust Co. now owns 237,030 shares of the company's stock worth $43,997,000 after purchasing an additional 9,073 shares in the last quarter. Institutional investors and hedge funds own  70.23% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of analysts have commented on the stock. UBS Group upped their price objective on shares of AbbVie from $195.00 to $220.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, November 7th. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $280.00 price target on the stock. Hsbc Global Res lowered shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, October 1st. Piper Sandler  reissued an &#34;overweight&#34; rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Finally, Bank of America increased their target price on AbbVie from $220.00 to $251.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued  a Hold rating to the company. According to data from MarketBeat, AbbVie  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $241.85.</p><ul><li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li></ul><p><b>View Our Latest Stock Report on ABBV</b></p><h2>AbbVie Trading Down 1.8%</h2><p>Shares of NYSE:ABBV opened at $227.57 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $402.20 billion, a P/E ratio of 108.37, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm has a fifty day moving average of $227.62 and a two-hundred day moving average of $206.42. </p><ul><li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to analysts' expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The business's revenue for the quarter was up 9.1% on a year-over-year basis.  AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie's payout ratio is 524.24%. </p><h2>About AbbVie</h2> (Free Report)<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>Read More</h2><ul><li>Five stocks we like better than AbbVie</li><li>Basic Materials Stocks Investing</li><li>3 Stocks to Buy for the Evolution of AI Infrastructure</li><li>Investing in Construction Stocks</li><li>How Semtech’s Data Center Chips Are Powering the AI Boom</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>Keysight Technologies' Surge: The Market Wakes Up to This AI Play</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Neuberger Berman Group LLC reduced its stake in AbbVie Inc. by 9.7% in Q2, owning 1,240,254 shares worth $230.2 million. Other investors adjusted their holdings, with some increasing their stakes. Analysts have mixed ratings on AbbVie, with a consensus target price of $241.85. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, and increased its dividend. The stock opened at $227.57, with a market cap of $402.2 billion.</p>

AbbVie Inc. $ABBV Holdings Decreased by Neuberger Berman Group LLC